PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Crawls 10,000+ sources around the clock and organizes the noise into verified stories — de-duplicated, bias-scored, and auto-tagged, with blindspot detection, trend analytics, anomaly alerts, translation, and custom digests or RSS. All in one live dashboard.

PR Newswire Technology

pressCenter

1h ago

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancertranslating…

Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approval comes four months ahead of PDUFA date NEW YORK, Sept. 16, 2026 /PRNewswire/…

Factuality

60/100

Political Bias

Center

Ownership

PR Digital Media

Country

Unknown

Keywords#Approval#Duration#Response#Updated#Advanced

Read Original ↗

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer | Pulse Aggregator